Low-dose prednisone and increased risk of development of bone metastases.
Body
J J
JJ
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary*; D001862:Bone Resorption / Q000139:chemically induced; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D011241:Prednisone / Q000009:adverse effects*
D018931:Antineoplastic Agents, Hormonal; D002945:Cisplatin; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate